Inovalon Holdings Inc

Inovalon — Merger or Acquisition (March 2018)

45 slides from Inovalon's merger presentation, Mar 7, 2018

  1. Slide 1: Acquiring ABILITY Network

    Acquiring ABILITY Network Expanding the Inovalon ONE™ Platform to 50,000 Provider Sites Creating a vertically integrated leader in cloud-based enablement of data-driven, value-based care March 7, 2018

  2. Slide 2: On Today's Call

    On Today‟s Call Keith Dunleavy, M.D. CEO & Chairman of Inovalon Mark A. Pulido CEO & Chairman of ABILITY Network 2 INOV & ABILITY Presentation (3.7.18) v1.0.0

  3. Slide 3: Cautionary Note Regarding Forward-Looking Statement

    Cautionary Note Regarding Forward-Looking Statement Certain statements contained in this presentation constitute forward-looking statements within the meaning of, and are intended to be covered by the safe harbor provisions of, Section 27A of the Securities Act of 1933, as amended, and Section 21E o

  4. Slide 4: A Powerful Combination

    A Powerful Combination The combination of Inovalon and ABILITY creates a vertically integrated leader in cloud-based enablement of data-driven, value-based care. 4 INOV & ABILITY Presentation (3.7.18) v1.0.0 + Through the Inovalon ONE™ Platform, Inovalon supports cloud-based, real-time connectivity,

  5. Slide 5: The Inovalon ONE Platform

    Payers Pharma Devices Diagnostics Post-Acute Providers Massive Data Assets Advanced Analytics Acute Providers Ambulatory Providers Intervention Toolsets 5 Data Visualization The Inovalon ONE™ Platform Home Care SNF Hospice + A vertically integrated cloud-based platform empowering the achievement of

  6. Slide 6: The Deal

    The Deal Inovalon has entered into a definitive agreement to acquire ABILITY Network for $1.2B, comprised of $1.1B in cash and $100M in restricted Inovalon equity.1 The transaction is expected to close in early April 2018, subject to customary closing conditions and regulatory approval. The combinat

  7. Slide 7: The Big Picture

    The Big Picture The entirety of the healthcare ecosystem is undergoing a massive transformation driven by the shift from volume-based to value-based forces. Data, its aggregation, analysis, and targeted application is the key to enabling the desired outcomes and economics within this new healthcare

  8. Slide 8: A Common Mission

    A Common Mission Inovalon and ABILITY share a common mission centered on enabling data- driven improvements in healthcare. Empowering Data-Driven Impact to Achieve Greater Quality and Economics in Healthcare Empowering value-based healthcare through data, connectivity, analytics, intervention, and r

  9. Slide 9: Meaningful Benefits to Healthcare

    • Achieves a vertically integrated cloud-based platform that empowers the achievement of real-time, value-based care from payers, manufacturers, and diagnostics all the way to the patient‟s point of care • Expands on the data scale, connectivity, and impact reach of data-driven healthcare for the en

  10. Slide 10: Highly Synergistic for Current Inovalon Customer Audience

    Highly Synergistic for Current Inovalon Customer Audience 10 INOV & ABILITY Presentation (3.7.18) v1.0.0 Payers Pharma Devices Diagnostics Synergistic Benefit to Inovalon‟s Existing Customer Audience Payers seek to achieve risk, quality, utilization, readmission, and retention goals – all better en

  11. Slide 11: Highly Synergistic for Current ABILITY Customer Audience

    11 INOV & ABILITY Presentation (3.7.18) v1.0.0 Post-Acute Providers Acute Providers Ambulatory Providers Home Care SNF Hospice Highly Synergistic for Current ABILITY Customer Audience The acute, post-acute, and ambulatory provider markets are eager to have access to more advanced analytics and value

  12. Slide 12: Greater Market Addressability

    Greater Market Addressability The combination of Inovalon and ABILITY is expected to be highly complementary, expanding the addressability of our market opportunity. 12 INOV & ABILITY Presentation (3.7.18) v1.0.0 2018 Payers $17.3bn Current Pharma/Life Sciences Products $7.0bn Current Providers Prod

  13. Slide 13: Expanding Connectivity & Datasets

    0 20,000 40,000 60,000 80,000 100,000 120,000 140,000 4Q13 1Q14 2Q14 3Q14 4Q14 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 C lin ic ia n C ou nt Illustrative of addition through combination 2018I 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

  14. Slide 14: Expand Reach & Accelerate Impact

    Expand Reach & Accelerate Impact Together we have the ability to empower real-time insight and impact, expanded reach and value achievement from the payer, manufacturer, and diagnostic, all the way down to the provider and patient at the point-of-care. 240M+ Patients 50K+ Provider Sites 14 INOV & AB

  15. Slide 15: ABILITY Network at a Glance

    ABILITY Network at a Glance Leading SaaS technology company that helps providers and payers simplify the administrative and clinical complexities of healthcare Offers the myABILITY® software platform, an integrated set of cloud-based applications that offers core connectivity, administrative, clinic

  16. Slide 16: The People

    The People Approximately 530 ABILITY team members bringing an expansion of depth, experience, and expertise. Mark Pulido – Chairman & Chief Executive Officer • Over 30 years of experience; joined ABILITY as Chairman in 2011 & as CEO in 2015 • Previously served as President & CEO of McKesson Corporat

  17. Slide 17: Strong, High Volume, High Velocity Salesforce

    135 Strong, High Volume, High Velocity Salesforce The ABILITY sales team provides a significant expansion in Inovalon‟s go-to-market capacity. 17 INOV & ABILITY Presentation (3.7.18) v1.0.0

  18. Slide 18: myABILITY cloud-based platform

    ABILITY has developed an easy-to-use, cloud-based platform, utilized by more than 44,000 provider sites to achieve greater effectiveness and efficiency across a spectrum of their provider-site needs - from quality and patient care protocol solutions, to revenue cycle management, business insights, a

  19. Slide 19: Exceptional Opportunity for New Product Development

    Exceptional Opportunity for New Product Development The point-of-care presence and the in-workflow nature of the myABILITY® workspace, coupled with the client base and capabilities of the Inovalon ONE™ Platform, provides extensive opportunity for new product development throughout the customer stack

  20. Slide 20: Illustrations

    Illustrations 20 INOV & ABILITY Presentation (3.7.18) v1.0.0

  21. Slide 21: Expanded Ambulatory Provider Value Realization

    21 INOV & ABILITY Presentation (3.7.18) v1.0.0 Expanded Ambulatory Provider Value Realization CCM & MACRA / MIPS Enablement In 2015, CMS introduced the Medicare Access and CHIP Reauthorization Act (MACRA) initiative to enable providers to receive additional quality-related payments for Medicare Fee

  22. Slide 22: More Efficient Payer & Provider Encounter Facilitation

    22 INOV & ABILITY Presentation (3.7.18) v1.0.0 More Efficient Payer & Provider Encounter Facilitation Aligning Needs, Timing & Resources Today Inovalon‟s analytics are engaged by health plans to identify millions of patients who are in need of clinical encounters to achieve improved quality outcomes

  23. Slide 23: More Advanced Post-Acute Care Provider Support

    23 INOV & ABILITY Presentation (3.7.18) v1.0.0 More Advanced Post-Acute Care Provider Support PAC Optimization Post-Acute Care (PAC) providers are under tremendous pressures to reduce cost, complications and readmission, while also improving outcomes and satisfaction. Inovalon‟s eP4™ Component withi

  24. Slide 24: Integrated Specialty Pharmacy Coordination

    24 INOV & ABILITY Presentation (3.7.18) v1.0.0 Integrated Specialty Pharmacy Coordination Seamlessness & Efficiency Specialty Pharmacies are responsible for the high-cost and high complexity cases of patients and their medications. The number of provider-side authorizations, verifications, data aggr

  25. Slide 25: Data-Driven Clinical Trial Process Support

    Data-Driven Clinical Trial Process Support CRO Solutioning Provider and patient identification, engagement, recruitment and clinical trial process management at the point-of-care brings a heavy management and cost burden to the pharmaceutical marketplace. Leveraging the Inovalon ONE™ Platform‟s conn

  26. Slide 26: Powering the Tech-Enabled Clinic

    26 INOV & ABILITY Presentation (3.7.18) v1.0.0 Powering the Tech-Enabled Clinic Connected, Data-Driven, Best Practices Employers are increasingly developing and investing in delivering data-driven, patient-centered care for their associates to differentiate their organizations, decrease overall cost

  27. Slide 27: Expanded Value Beyond

    Expanded Value Beyond Supporting alignment between the needs and goals of payers and the providers who constitute their networks The ability to obtain & leverage Natural Language Processing (NLP) to form unique clinical datasets from across hundreds of thousands of clinicians in real-time Enabling a

  28. Slide 28: Financial Metrics

    Financial Metrics 28 INOV & ABILITY Presentation (3.7.18) v1.0.0

  29. Slide 29: Increasing Mix of Subscription-Based Platform Offerings

    Increasing Mix of Subscription-Based Platform Offerings 15% 74% 11% 19% 66% 15% Inovalon 2017 Pro-Forma 2017 Subscription-Based Platform Offerings Services Legacy Solutions 29 INOV & ABILITY Presentation (3.7.18) v1.0.0 99% 1% Note: Based on financial results of Inovalon (audited) and ABILITY (unaud

  30. Slide 30: Increasing Client-Base Diversification

    Increasing Client-Base Diversification Payer Provider Pharma Devices 15% 69% 15% 1% 91% 9% 54% 34% 11% 1% Inovalon 2017 ABILITY 2017 30 INOV & ABILITY Presentation (3.7.18) v1.0.0 Pro-Forma 2017 Note: Based on financial results of Inovalon (audited) and ABILITY (unaudited). Pro-forma results based o

  31. Slide 31: Decreasing Client Concentration

    Decreasing Client Concentration Top-10 Client Revenue Other Client Revenue 53% 47% 41% 59% 31 95% 5% Note: Based on financial results of Inovalon (audited) and ABILITY (unaudited). Pro-forma results based on the combination of Inovalon and ABILITY without any adjustments. Inovalon 2017 Pro-Forma 201

  32. Slide 32: Gross Margin Expansion

    Gross Margin Expansion 66.4% 83.7% 70.5% Gross Margin 32 INOV & ABILITY Presentation (3.7.18) v1.0.0 66.4% 83.7% Note: Based on financial results of Inovalon (audited) and ABILITY (unaudited). Pro-forma results based on the combination of Inovalon and ABILITY without any adjustments. Inovalon 2017 P

  33. Slide 33: Adjusted EBITDA Margin Expansion

    Adjusted EBIDTA Margin Expansion 24.3% 51.6%1 30.7% Adjusted EBITDA Margin 33 INOV & ABILITY Presentation (3.7.18) v1.0.0 1 Ability 2017 Adjusted EBIDTA margin reflects certain credit agreement adjustments and anticipated cost savings expected to be realized within eighteen months. Note: Based on fi

  34. Slide 34: Guidance Update

    Guidance Update1 34 INOV & ABILITY Presentation (3.7.18) v1.0.0 1 The Company„s previously provided guidance of February 20, 2018 remains unchanged except for the addition of ABILITY Network‟s impact presuming an acquisition closing in early April 2018. Note: All dollars shown in millions. All proje

  35. Slide 35: Revenue Offering Mix

    Revenue Offering Mix The following preliminary guidance is being provided, presuming an early April 2018 deal closure. The Company‟s updated guidance will be confirmed following closing. 35 INOV & ABILITY Presentation (3.7.18) v1.0.0 Subscription-Based Platform Offerings Services Legacy Solutions $4

  36. Slide 36: Revenue

    Revenue 36 INOV & ABILITY Presentation (3.7.18) v1.0.0 $240 $300 $296 $362 $437 $428 $449 $568 - $593 2011 2012 2013 2014 2015 2016 2017 2018G Note: CAGR calculations undertaken to the mid-point of 2018 Guidance. 2011 – 2018G CAGR 13% The following preliminary guidance is being provided, presuming a

  37. Slide 37: Adjusted EBITDA

    $58 $108 $72 $134 $152 $100 $109 $163 - $174 24% 36% 24% 37% 35% 23% 24% 29% 2011 2012 2013 2014 2015 2016 2017 2018G Adjusted EBITDA 37 INOV & ABILITY Presentation (3.7.18) v1.0.0 % of Revenue Note: CAGR calculations undertaken to the mid-point of 2018 Guidance. 2011 – 2018G CAGR 17% The following

  38. Slide 38: Debt, Cash Flow & Leverage Pay-Down

    Debt, Cash Flow & Leverage Pay-Down 38 INOV & ABILITY Presentation (3.7.18) v1.0.0 • Inovalon will finance the transaction through $100M of restricted equity1, cash on hand, and borrowings from a new $980M term loan, which will also be used to pay off and replace the Company‟s existing credit facili

  39. Slide 39: Financial Table

    Financial Table The following preliminary guidance is being provided, presuming an early April 2018 deal closure. The Company‟s updated guidance will be confirmed following closing. 39 INOV & ABILITY Presentation (3.7.18) v1.0.0 Financial Metric Updated Guidance Range1 Provided March 7, 2018 Previou

  40. Slide 40: The Inovalon ONE Platform

    Payers Pharma Devices Diagnostics Post-Acute Providers Massive Data Assets Advanced Analytics Acute Providers Ambulatory Providers Intervention Toolsets 40 Data Visualization The Inovalon ONE™ Platform Home Care SNF Hospice + A vertically integrated cloud-based platform empowering the achievement of

  41. Slide 41: Appendix

    Appendix 41 INOV & ABILITY Presentation (3.7.18) v1.0.0

  42. Slide 42: Deal Notes

    Deal Notes 42 INOV & ABILITY Presentation (3.7.18) v1.0.0 1. ABILITY Network Revenue Metrics: ABILITY‟s revenue growth rate in 2016 and 2017 was 10.1% and 10.0% respectively. In 2018, the revenue resulting from the incorporation of ABILITY into Inovalon will be decremented by approximately $8 millio

  43. Slide 43: Reconciliation of Forward-Looking Preliminary Guidance Adjusted EBITDA

    Reconciliation of Forward-Looking Preliminary Guidance Adjusted EBITDA Inovalon defines Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA) as net income calculated in accordance with GAAP, adjusted for the impact of depreciation and amortization, realized losse

  44. Slide 44: Reconciliation of Forward-Looking Preliminary Guidance Non-GAAP Net Income

    Reconciliation of Forward-Looking Preliminary Guidance Non-GAAP Net Income Inovalon defines Non-GAAP net income as net income calculated in accordance with GAAP, adjusted to exclude tax-affected stock-based compensation expense, acquisition costs, amortization of acquired intangible assets, tax on e

  45. Slide 45: Healthcare Empowered

    Healthcare Empowered® 45 INOV & ABILITY Presentation (3.7.18) v1.0.0

Inovalon Holdings — Merger or Acquisition (March 2018) on 6ix